Cantor Fitzgerald Issues Pessimistic Forecast for AbbVie (NYSE:ABBV) Stock Price

Posted by Anthony Miller on Apr 8th, 2026

AbbVie (NYSE:ABBV – Get Free Report) had its price target decreased by investment analysts at Cantor Fitzgerald from $250.00 to $240.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 16.39% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on the company. Piper Sandler increased their price objective on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. William Blair reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. The Goldman Sachs Group restated a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a report on Tuesday, January 20th. Finally, Evercore reduced their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $252.65.

Read Our Latest Analysis on ABBV

AbbVie Stock Performance

Shares of NYSE ABBV opened at $206.21 on Wednesday. The business has a 50 day simple moving average of $220.95 and a 200 day simple moving average of $224.28. AbbVie has a 52 week low of $164.39 and a 52 week high of $244.81. The stock has a market cap of $364.61 billion, a price-to-earnings ratio of 87.38, a PEG ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the prior year, the business posted $2.16 earnings per share. The business’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts predict that AbbVie will post 12.31 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.25% of the company’s stock.

Hedge Funds Weigh In On AbbVie

A number of large investors have recently added to or reduced their stakes in the company. Brighton Jones LLC grew its position in AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares during the period. Schnieders Capital Management LLC. raised its stake in AbbVie by 5.0% in the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after buying an additional 789 shares during the period. Gamco Investors INC. ET AL lifted its position in shares of AbbVie by 18.0% in the second quarter. Gamco Investors INC. ET AL now owns 15,750 shares of the company’s stock valued at $2,923,000 after buying an additional 2,402 shares during the last quarter. Finally, Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna bought a new position in shares of AbbVie during the 2nd quarter worth approximately $314,000. Institutional investors own 70.23% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: New dermatology data presented at the American Academy of Dermatology strengthen long‑term efficacy/safety and quality‑of‑life profiles for Skyrizi (risankizumab) and Rinvoq (upadacitinib); FDA label expansion for Skyrizi (genital and scalp psoriasis) supports continued market momentum for AbbVie’s high‑growth immunology portfolio. Can AbbVie’s New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
Positive Sentiment: J.P. Morgan issued a constructive call with a $260 price target, framing recent weakness as a buying opportunity and providing a potential catalyst if sentiment improves. AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target
Positive Sentiment: Allergan Aesthetics initiatives (Botox® Cosmetic grants program and a new Allergan Medical Institute center) bolster the aesthetics franchise’s brand/education footprint and may support non‑immunology revenue. BOTOX® Cosmetic Empowers Women Entrepreneurs Allergan Aesthetics Third State-of-the-Art AMI Center Opens
Neutral Sentiment: AbbVie updated investors on a real‑world Parkinson’s observational study in Belgium — progress to monitor but not an immediate revenue driver. AbbVie’s Real‑World Parkinson’s Study in Belgium
Neutral Sentiment: AbbVie faces an earnings event (Q1) at the end of April — analysts and investors are positioning ahead of guidance and cadence comments. Should You Buy AbbVie Stock Before April 29?
Negative Sentiment: AbbVie placed Humira on the White House’s TrumpRx platform at a steep (~86%) discount — a pricing concession that could weigh on Humira revenue and raises fresh questions about valuation and pricing strategy for legacy products. AbbVie Puts Humira on TrumpRx at Steep Discount Humira’s TrumpRx Discount Raises New Questions For AbbVie Valuation
Negative Sentiment: Shares have underperformed peers and recently slipped despite broader market gains, reflecting investor concern over Humira pricing, competition and the high earnings bar for 2026. AbbVie Stock Drops Despite Market Gains

About AbbVie

(Get Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.